title: Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection.
abstract: OBJECTIVE
  Clinical and experimental data suggest that gut-derived endotoxins are an important pathogenic factors for progression of chronic liver disease. Recently, a C-T (-159) polymorphism in the promoter region of the CD14 gene was detected and found to confer increased CD14 expression and to be associated with advanced alcoholic liver damage. Here, we investigated this polymorphism in patients with less advanced alcoholic liver disease (ALD) and chronic hepatitis C virus (HCV) infection.
  
  
  METHODS
  CD14 genotyping was performed by PCR-RFLP analysis in (a) 121 HCV patients, (b) 62 patients with alcohol-associated cirrhosis (Alc-Ci), (c) 118 individuals with heavy alcohol abuse without evidence of advanced liver damage (Alc-w/o Ci), and (d) 247 healthy controls. Furthermore, serum levels of soluble CD14 (sCD14) and transaminases were determined.
  
  
  RESULTS
  The TT genotype was significantly more frequent in Alc-Ci compared to Alc-w/o Ci or controls (40.3% vs 23.7% or 24.0%, respectively). In Alc-w/o Ci, serum levels of transaminases did not differ significantly between patients with different CD14 genotypes. In HCV patients, TT-homozygotes had significantly higher sCD14 levels and sCD14 serum levels were significantly higher in patients with advanced fibrosis or cirrhosis. However, no association was found between CD14 genotypes and histological staging or grading.
  
  
  CONCLUSIONS
  Considering serum transaminases as surrogate markers for alcoholic liver damage, the CD14 polymorphism seems to exhibit different effects during the course of ALD. Differences in genotype distribution between cirrhotic HCV patients and alcoholics and the known functional impact of this polymorphism on CD14 expression levels further indicate differences in the pathophysiological role of CD14 and CD14-mediated lipopolysaccharides signal transduction with regard to the stage as well as the type of the underlying liver disease.
authors.affiliation: Department of Internal Medicine I, University of Regensburg, Regensburg D-93042, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Meiler
authors.forename: M
authors.initials: M
authors.lastname: Muhlbauer
authors.forename: M
authors.initials: M
authors.lastname: Johann
authors.forename: A
authors.initials: A
authors.lastname: Hartmann
authors.forename: B
authors.initials: B
authors.lastname: Schnabl
authors.forename: N
authors.initials: N
authors.lastname: Wodarz
authors.forename: G
authors.initials: G
authors.lastname: Schmitz
authors.forename: J
authors.initials: J
authors.lastname: Scholmerich
authors.forename: C
authors.initials: C
authors.lastname: Hellerbrand
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000097:blood / Q000235:genetics*; D008108:Liver Diseases, Alcoholic / Q000235:genetics* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D012189:Retrospective Studies
chemical_list: D018950:Lipopolysaccharide Receptors